Improving the detection and management of AF in the North West Coast


The Innovation Agency (Academic Health Science Network for the North West Coast) has been one of a number of organisations to deliver improvements in care for people with AF across a healthcare system.

In 2015, the AHSN Network set ambitious targets to systematically improve the detection, diagnosis and treatment of patients with AF. At this time the North West Coast’s baseline data (QOF 15/16) showed that:

• 24,210 people were estimated to have undetected AF.

• 76% of people with high risk AF were treated with an anticoagulation therapy (AT).

The Innovation Agency was keen to ensure that local best practice was understood and promoted, whilst acknowledging that sustainable improvements in the outcomes for patients with AF would require greater collaboration and integrated system working.

More Additional Reading

Independent evaluation of the AHSN Network mobile ECG roll-out programme

The national roll out of mobile ECG devices by Academic Health Science Networks (AHSNs) was born out of a system-wide procurement initiative to promote the uptake of a digital technology (mobile ECG). This was a novel approach to facilitate innovation adoption which prompted the AHSN Network to commission an independent evaluation of the roll out, at AHSN level, to understand its effectiveness, and in particular what can be learned about: the environments in which the devices are most effective, what characterises an effective implementation package, the impact on the market place, patients (through AF detection) and providers; and the health economic aspects of this type of programme.

Clinical guide for the management of anticoagulant services during the coronavirus pandemic

Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS, the way we deliver anticoagulants may need to change. We should seek the best local solutions to continue the safe management of patients on anticoagulation while protecting resources for the response to coronavirus

Public Health England CVD Ambitions

A new coalition led by Public Health England (PHE) and NHS England has announced the first ever national ambitions to improve the detection and treatment of atrial fibrillation, high blood pressure and high cholesterol (A-B-C) – the major causes of cardiovascular disease (CVD).
This site is intended for Healthcare Professionals only

If you are not a healthcare professional, please Click Here